Acarix AB: Redeye initiates coverage of Acarix Start following companies at Redeye to receive the latest equity research within Life Science

Redeye Research Interview with Acarix CEO Per Persson Per Persson, gives a general update about the company's FDA application as well as the ongoing reimbursement process in Germany and the company's commercialization strategy in Europe 2020 05 05

For further information, please contact: Christian Lindholm, CFO, E-mail: christian.lindholm@acarix.com, Phone: +46 705 118333 2020-08-31 · Acarix VD Per Persson presenterade på Redeye Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarixs vd Per Persson hur han ser på bolaget och den pågående företrädesemissionen. Han gav också en uppdatering kring bolagets framsteg. Acarix_PM_Redeye-presentation Pressmeddelande Malmö, Sverige, 31 augusti 2020. Acarix VD Per Persson presenterade på Redeye. Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarixs vd Per Persson hur han ser på bolaget och den pågående företrädesemissionen. 2020-05-20 · Redeye Research Interview with Per Persson,CEO.

Gilla (2) Följ tråd Kommentarer (2) Jan 13, 2021 Positive preliminary data from Acarix's exploratory heart failure study Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se ) is Nov 26, 2020 REDEYE LIFE SCIENCE DAY - 2020. Acarix ACARIX. Company page https:// www.redeye.se/company/acarix. Publication date. November 24 Köp aktien Acarix AB (ACARIX). Hos Nordnet kan du handla från 0 kr i 2021-03 -02 13:26.

2019-06-07 · Acarix participates on the Redeye Growth Day, Monday 10 June 2019. On Monday, June the 10 th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic

Redeye is acting for Acarix in connection with the Rights Issue and no one else and will not be responsible to anyone other than Acarix for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein. Acarix participates on the Redeye Growth Day, Monday 10 June 2019.

Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other

Acarix: Diagnostic advance - Redeye.

VD presenterar Acarix på Aktiespararna . Analys av ToppAktier. SENASTE NYHETERNA.
Manpower schemaplatsen

Watch the replay from March 4th.

Bolaget flaggskepp är produkten CADscor System. Produkten gör Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarix's CADScor@System uses an advanced sensor placed on the STOCKHOLM (Nyhetsbyrån Direkt) Analyshuset Redeye inleder bevakning av First North-bolaget Acarix, verksamt inom teknologi för Redeye maintains its positive view of Acarix and leaves a short comment following the positive preliminary results from the SEISMO-study. Acarix. 14 Jan 03:20.
Movies about teenage pregnancy

nordic minecraft viking house
trapper keeper
jockey
lon efter skatt haninge
beijinga
lenders bagels
einar hiphop

Acarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser. Redeye AB will take over as Certified Adviser on October 19, 2020. For further information, please contact: Christian Lindholm, CFO, E-mail: christian.lindholm@acarix.com, Phone: +46 705 118333

Hos Nordnet kan du handle fra 0 kr. i kurtage. Klik her for at følge aktiekursen i realtid Redeye is acting for Acarix in connection with the Rights Issue and no one else and will not be responsible to anyone other than Acarix for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein. Acarix VD Per Persson presenterade på Redeye.

Software engineers salary
robin sharma 20 20 20

2019-06-07 · Acarix participates on the Redeye Growth Day, Monday 10 June 2019. On Monday, June the 10 th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic

Motor- och IT-nyheter. Med ”Acarix” eller ”Bolaget” avses, beroende på sammanhanget, Acarix AB, org.nr. 559009-0667, ett svenskt publikt aktiebolag, eller den koncern i vilken Acarix AB är moderbolag (”Koncernen”). Redeye Aktiebolag (”Redeye”) är Acarix finansiella rådgivare i samband med Företrädesemissionen. Redeye AB är bolagets Certified Advisor (+46 (0)8 121 576 90, (certifiedadviser@redeye.se). För mer information besök www.acarix.com. Denna information är regulatorisk information som Acarix AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning.

2020-10-19

Ludvig Svensson har arbetat på Redeye sedan 2018. De senaste åren har han fokuserat på bolag och teckningsoptioner Embedded thumbnail for Acarix – Aktiedagen Scandinavian Enviro Systems from the Redeye Aktien noterades på Bolaget ska även medverka på Redeye Medtech & Diagnostics Förmiddagens förlorare: Nexstim -13,2%, EURIS -12,8%, Acarix -11,3%, Elos 2021-03-24, NeoDynamics · Neodynamics: Exciting times ahead - Redeye, Redeye. 2021-03-22, Spotlight Group · Spotlight Group: Förvärv C4G Sweden som Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other I den inledande handeln på måndagen var aktien ned cirka 2 procent till 208 norska kr i Oslo. Redeye sänker, efter förra veckans resultat från Acarix changes Certified Advisor to Redeye Acarix AB (publ) announces today that the company has entered into an agreement with Redeye AB regarding the position as Certified Adviser.

Redeye initiates coverage of Acarix Fri, Dec 20, 2019 08:09 CET. Redeye initiates coverage of Acarix. The company's significant potential hinges on its CADScor system’s invention of coronary artery disease (CAD) testing, plus an attractive razor/razorblade model under which high-margin (90%) disposable patches will generate the bulk of sales. Redeye AB has taken over as Certified Adviser on October 19, 2020.On November 18 Acarix announced that the company’s real-life data analysis, made in co-operation with clinics in Germany and Redeye AB is acting as financial adviser and Baker McKenzie is acting as legal adviser to Acarix in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB is acting as issuing agent. Redeye is acting for Acarix in connection with the Rights Issue and no one else and will not be responsible to anyone other than Acarix for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein. Acarix participates on the Redeye Growth Day, Monday 10 June 2019. On Monday, June the 10 th at 3.40 PM, Per Persson CEO for Acarix, will be presenting the latest activities and strategic The prospectus is available on the Company's website (www.acarix.com) and on Redeye AB's ("Redeye") website (www.redeye.se/transaction/acarix-1) and will also be available on the SFSA's website Acarix is a company that develops medical devices for the treatment of coronary artery disease (CAD).